Urology Austin PLLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,029,297	107
2024	Research	$873,427	64
2023	Research	$36,951	8
2022	Research	$43,047	14
2021	Research	$162,134	9
2020	Research	$24,629	1

Breakdown

Who paid Research payments · program years 2020–2025

Janssen Research & Development, LLC $1,738,890 150 payments
Sumitomo Pharma America, Inc. $197,640 24 payments
Pfizer Inc. $164,152 6 payments
Teleflex Medical Incorporated $21,973 14 payments
Teleflex LLC $20,300 1 payment
Arrow International, Inc. $19,540 7 payments
AstraZeneca Pharmaceuticals LP $6,990 1 payment

Studies the money was for Research payments · program years 2020–2025

A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc $711,489 33 payments
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM $372,422 28 payments
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc $209,818 15 payments
A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $170,089 22 payments
A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer $139,524 5 payments
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) $94,021 9 payments
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) $73,865 1 payment
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo $65,717 20 payments
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions $56,533 4 payments
A Multi Center Open label Single arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy ADT in Treatment naive Participants Who Have Undergone Radical Prostatectomy RP for Nonmetastatic Prostate Cancer and Who Are at High Risk for Metastases $55,055 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.